We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Boston Scientific Is Expanding Its Global Growth
Read MoreHide Full Article
Key Takeaways
Boston Scientific posted 12% APAC sales growth in Q1, led by Japan and China strength.
BSX expects EMEA sales to improve with FARAPULSE, WATCHMAN and Neuromodulation momentum.
China growth was driven by imaging tech and OPAL HDx approval supporting FARAPULSE expansion.
Boston Scientific (BSX - Free Report) continues to expand its operations outside the United States, supported by a diversified portfolio and strong commercial execution. The company’s international business remains a key long-term growth driver, supported by new product approvals, ecosystem expansion and continued penetration in high-growth APAC markets.
In Europe, the Middle East and Africa (“EMEA”), operational sales grew 1% in the first quarter of 2026. Growth in the quarter was driven by FARAPULSE, coronary and vascular therapies and Neuromod. Management expects sales in this region to improve with the annualization of the ACURATE discontinuation in the second quarter and ongoing momentum from FARAPULSE, WATCHMAN and other key products.
In the Asia Pacific region, operational sales increased 12% in the first quarter, driven by double-digit growth in Japan and China. Japan’s performance was supported by its differentiated PFA ecosystem, including OPAL, FARAVIEW, and FARAPULSE, along with strong adoption of WATCHMAN FLX Pro.
China also delivered robust growth despite VBP-related impacts, led by the interventional cardiology portfolio, particularly imaging technologies. Progress toward FARAPULSE goals remains steady in a competitive Chinese market, supported by NMPA approval of the OPAL HDx mapping system and the continued expansion of the PFA platform with FARAVIEW.
Peer Update
In the first quarter of 2026, Stryker (SYK - Free Report) reported international organic sales growth of 3.9%, outperforming its U.S. growth of 1.9%, despite a significant cyber incident that disrupted operations globally. SYK has built much of its international expansion over the past decade on Europe, where the company gained significant market share through products such as Mako robotic systems, trauma devices and advanced imaging technologies.
Japan has also emerged as one of Stryker’s fastest-growing markets outside the United States. In addition, Stryker highlighted accelerating momentum in India, Korea, East Asia, and the Middle East, particularly Saudi Arabia, where healthcare infrastructure investment is increasing rapidly.
In the third quarter of fiscal 2026, Medtronic (MDT - Free Report) delivered balanced international revenue growth, including high-single-digit growth in Western Europe and mid-single-digit growth across the United States and Japan. The company also posted low-single-digit growth in China while navigating ongoing but manageable volume-based procurement (VBP) pressures in select businesses.
The Structural Heart business delivered a stronger quarter internationally and continued gaining share in Europe. The Diabetes unit also recorded solid performance across international markets. In January 2026, Medtronic’s Affera Sphere-360 catheter received the CE Mark approval in Europe, with commercialization expected to begin shortly.
BSX Stock Price Performance
Shares of Boston Scientific have lost 48.5% over the past year compared with the industry’s decline of 30.2%. The S&P 500 composite has grown 30.1% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-sales ratio (P/S) of 3.52X, above the industry median of 3.03X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s 2026 earnings has moved south 2% over the past 30 days.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Boston Scientific Is Expanding Its Global Growth
Key Takeaways
Boston Scientific (BSX - Free Report) continues to expand its operations outside the United States, supported by a diversified portfolio and strong commercial execution. The company’s international business remains a key long-term growth driver, supported by new product approvals, ecosystem expansion and continued penetration in high-growth APAC markets.
In Europe, the Middle East and Africa (“EMEA”), operational sales grew 1% in the first quarter of 2026. Growth in the quarter was driven by FARAPULSE, coronary and vascular therapies and Neuromod. Management expects sales in this region to improve with the annualization of the ACURATE discontinuation in the second quarter and ongoing momentum from FARAPULSE, WATCHMAN and other key products.
In the Asia Pacific region, operational sales increased 12% in the first quarter, driven by double-digit growth in Japan and China. Japan’s performance was supported by its differentiated PFA ecosystem, including OPAL, FARAVIEW, and FARAPULSE, along with strong adoption of WATCHMAN FLX Pro.
China also delivered robust growth despite VBP-related impacts, led by the interventional cardiology portfolio, particularly imaging technologies. Progress toward FARAPULSE goals remains steady in a competitive Chinese market, supported by NMPA approval of the OPAL HDx mapping system and the continued expansion of the PFA platform with FARAVIEW.
Peer Update
In the first quarter of 2026, Stryker (SYK - Free Report) reported international organic sales growth of 3.9%, outperforming its U.S. growth of 1.9%, despite a significant cyber incident that disrupted operations globally. SYK has built much of its international expansion over the past decade on Europe, where the company gained significant market share through products such as Mako robotic systems, trauma devices and advanced imaging technologies.
Japan has also emerged as one of Stryker’s fastest-growing markets outside the United States. In addition, Stryker highlighted accelerating momentum in India, Korea, East Asia, and the Middle East, particularly Saudi Arabia, where healthcare infrastructure investment is increasing rapidly.
In the third quarter of fiscal 2026, Medtronic (MDT - Free Report) delivered balanced international revenue growth, including high-single-digit growth in Western Europe and mid-single-digit growth across the United States and Japan. The company also posted low-single-digit growth in China while navigating ongoing but manageable volume-based procurement (VBP) pressures in select businesses.
The Structural Heart business delivered a stronger quarter internationally and continued gaining share in Europe. The Diabetes unit also recorded solid performance across international markets. In January 2026, Medtronic’s Affera Sphere-360 catheter received the CE Mark approval in Europe, with commercialization expected to begin shortly.
BSX Stock Price Performance
Shares of Boston Scientific have lost 48.5% over the past year compared with the industry’s decline of 30.2%. The S&P 500 composite has grown 30.1% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-sales ratio (P/S) of 3.52X, above the industry median of 3.03X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s 2026 earnings has moved south 2% over the past 30 days.
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.